AstraZeneca’s (AZN) “Buy” Rating Reaffirmed at Shore Capital

Shore Capital reiterated their buy rating on shares of AstraZeneca (LON:AZN) in a research report released on Tuesday, MarketBeat.com reports.

Several other brokerages have also recently weighed in on AZN. Berenberg Bank raised their price objective on AstraZeneca from £120 ($152.52) to £130 ($165.23) and gave the company a buy rating in a report on Friday, May 3rd. Deutsche Bank Aktiengesellschaft reiterated a hold rating and issued a £105 ($133.45) price target on shares of AstraZeneca in a research note on Tuesday, April 23rd. JPMorgan Chase & Co. restated an overweight rating on shares of AstraZeneca in a research note on Thursday, April 4th. BMO Capital Markets reiterated an outperform rating on shares of AstraZeneca in a report on Monday, February 12th. Finally, UBS Group reduced their target price on shares of AstraZeneca from £107 ($135.99) to GBX 9,900 ($125.83) and set a sell rating for the company in a report on Monday, February 12th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and an average price target of £118 ($149.97).

AstraZeneca Stock Performance

Shares of AZN stock opened at £122.96 ($156.28) on Tuesday. The company has a market capitalization of £190.59 billion, a P/E ratio of 3,842.50, a price-to-earnings-growth ratio of 0.95 and a beta of 0.16. AstraZeneca has a 52 week low of GBX 9,461 ($120.25) and a 52 week high of £124.88 ($158.72). The company has a debt-to-equity ratio of 92.51, a quick ratio of 0.59 and a current ratio of 0.89. The company’s 50 day moving average price is £113.69 and its two-hundred day moving average price is £106.82.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.